TBPH

SEC source: 0001589602-26-000005 · form4-09252026_120944.xml · nonDerivative · entry 1

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,009

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · derivative · entry 6

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 515,000 shares

Expires 2032-02-24

F4 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.

F4 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 5

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 0

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 4

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Indirect · As Custodian

Disclosed balance after: 0

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 3

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 2

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,875

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,750

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 3

Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.

SEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 2

Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,439

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 1

Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,875

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0002012524-26-000011 · form4-09252026_120941.xml · derivative · entry 3

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 37,500 shares

Expires 2030-03-01

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0002012524-26-000011 · form4-09252026_120941.xml · nonDerivative · entry 2

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0002012524-26-000011 · form4-09252026_120941.xml · nonDerivative · entry 1

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,718

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001966698-26-000011 · form4-09252026_120901.xml · nonDerivative · entry 3

Grimaud Brett A. · CIK 0001966698 · SVP, GEN COUNSEL AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.

SEC source: 0001966698-26-000011 · form4-09252026_120901.xml · nonDerivative · entry 2

Grimaud Brett A. · CIK 0001966698 · SVP, GEN COUNSEL AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,439

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0001966698-26-000011 · form4-09252026_120901.xml · nonDerivative · entry 1

Grimaud Brett A. · CIK 0001966698 · SVP, GEN COUNSEL AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,251

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001898490-26-000017 · form4-09252026_120949.xml · derivative · entry 3

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 150,000 shares

Expires 2028-07-31

F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. However, any Company Option that has an exercise price per Ordinary Share that is greater than or equal to the Per Share Cash Consideration was cancelled and ceased to exist and the holder of any such Company Option was not entitled to payment of any consideration therefor.

SEC source: 0001898490-26-000017 · form4-09252026_120949.xml · nonDerivative · entry 2

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

SEC source: 0001898490-26-000017 · form4-09252026_120949.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,062

F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

SEC source: 0001898490-26-000014 · form4-09172026_090959.xml · nonDerivative · entry 3

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 213,476

F1 · price: This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001898490-26-000014 · form4-09172026_090959.xml · nonDerivative · entry 2

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,133

F1 · price: This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001898490-26-000014 · form4-09172026_090959.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 223,461

F1 · price: This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0002012524-26-000008 · form4-08242026_100836.xml · nonDerivative · entry 1

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,826

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001966698-26-000008 · form4-08242026_100841.xml · nonDerivative · entry 1

Grimaud Brett A. · CIK 0001966698 · SVP, GEN COUNSEL AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,168

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001898490-26-000012 · form4-08242026_100811.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,790

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001302443-26-000012 · form4-08242026_100811.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,611,022

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001961289-26-000008 · form4-08242026_100819.xml · nonDerivative · entry 1

Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 336,841

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001877589-26-000002 · primary_doc.xml · nonDerivative · entry 2

Samaha Eli · CIK 0001877589 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,167,489

F2 · price: The sales price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F1 · ownership.nature: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

SEC source: 0001877589-26-000002 · primary_doc.xml · nonDerivative · entry 1

Samaha Eli · CIK 0001877589 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,173,053

F1 · ownership.nature: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

SEC source: 0001877589-26-000001 · primary_doc.xml · nonDerivative · entry 3

Samaha Eli · CIK 0001877589 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,174,453

F3 · price: The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.00 to $17.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

SEC source: 0001877589-26-000001 · primary_doc.xml · nonDerivative · entry 2

Samaha Eli · CIK 0001877589 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,212,252

F2 · price: The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.13 to $17.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

SEC source: 0001877589-26-000001 · primary_doc.xml · nonDerivative · entry 1

Samaha Eli · CIK 0001877589 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 9,237,279

F1 · price: The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.07 to $17.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F4 · ownership.nature: These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the managing partner of Madison Avenue Partners, LP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

SEC source: 0002012524-26-000006 · form4-06232026_090617.xml · nonDerivative · entry 1

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,084

SEC source: 0001898490-26-000010 · form4-06172026_110631.xml · nonDerivative · entry 3

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 232,457

F1 · price: This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001898490-26-000010 · form4-06172026_110631.xml · nonDerivative · entry 2

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,114

F1 · price: This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001898490-26-000010 · form4-06172026_110631.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,442

F1 · price: This transaction was executed in multiple trades at prices from $16.21 to $16.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001270734-26-000004 · form4-06172026_010650.xml · derivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001270734-26-000004 · form4-06172026_010650.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,074

SEC source: 0001199297-26-000003 · form4-06172026_010636.xml · derivative · entry 2

MITCHELL DEAN J · CIK 0001199297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001199297-26-000003 · form4-06172026_010636.xml · nonDerivative · entry 1

MITCHELL DEAN J · CIK 0001199297 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,213

SEC source: 0001589602-26-000002 · form4-06172026_010655.xml · derivative · entry 2

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001589602-26-000002 · form4-06172026_010655.xml · nonDerivative · entry 1

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,989

SEC source: 0001833453-26-000006 · form4-06172026_010638.xml · derivative · entry 2

GRAY SUSANNAH · CIK 0001833453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001833453-26-000006 · form4-06172026_010638.xml · nonDerivative · entry 1

GRAY SUSANNAH · CIK 0001833453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,146

SEC source: 0001625377-26-000004 · form4-06172026_010644.xml · derivative · entry 2

O'Connor Donal · CIK 0001625377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,398

Underlying: Ordinary Shares · 13,398 shares

Expires 2036-06-11

F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

SEC source: 0001625377-26-000004 · form4-06172026_010644.xml · nonDerivative · entry 1

O'Connor Donal · CIK 0001625377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,213

SEC source: 0002012524-26-000004 · form4-05222026_100507.xml · nonDerivative · entry 1

Miller Aine · CIK 0002012524 · SVP, DEV & HEAD OF IRE OFFICE

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,334

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001966698-26-000006 · form4-05222026_100551.xml · nonDerivative · entry 1

Grimaud Brett A. · CIK 0001966698 · SVP, GEN COUNSEL AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 363,120

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001898490-26-000008 · form4-05222026_100557.xml · nonDerivative · entry 1

Farnum Rhonda · CIK 0001898490 · SVP, COMM & MEDICAL AFFAIRS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,771

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

SEC source: 0001302443-26-000006 · form4-05222026_100553.xml · nonDerivative · entry 1

Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,631,056

F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.